Leukapheresis Market: Market Size & Forecast 2026

Leukapheresis is a specialized form of apheresis that isolates white blood cells, or leukocytes, from a patient's blood by passing it through a centrifugal separator while returning red blood cells, plasma, and platelets to the donor. The procedure serves two primary clinical roles: therapeutic leukoreduction to rapidly reduce dangerously elevated white blood cell counts in conditions such as hyperleukocytosis associated with acute leukemias, and cell collection for downstream applications including stem cell transplantation and cellular immunotherapy manufacturing. It is performed in hospital-based apheresis programs, blood collection centers, and specialized cellular therapy facilities using automated instrumentation paired with single-use disposable sets.

• •Used for both therapeutic leukoreduction in leukemia management and donor cell collection for stem cell and immunotherapy programs
• •Represents a specific apheresis modality focused on leukocyte isolation rather than plasma, platelets, or red cell removal
• •Requires automated apheresis instruments and disposable tubing sets that are consumed per procedure

Rising global incidence of hematological malignancies, including leukemias and lymphomas, increases demand for leukapheresis as a therapeutic intervention and supportive care measure for cancer patients. The expanding pipeline and commercial adoption of adoptive cell therapies, particularly CAR-T cell treatments, have created sustained demand for standardized, high-quality autologous cell collection procedures that begin with leukapheresis. An aging global population, improving access to cellular medicine in emerging economies, and ongoing clinical development of new cell and gene therapies collectively expand the addressable patient base for apheresis services.

• •Growing cancer burden and rising leukemia incidence drive therapeutic demand for leukapheresis procedures
• •Expansion of cell and gene therapy programs relies on leukapheresis as the initial collection step for manufacturing autologous products
• •Increased clinical adoption of automated systems and expanding indications support broader market utilization

The market is organized around apheresis instrumentation and disposable consumables, with consumables representing a larger and recurring revenue stream given their single-use nature per collection procedure. Application segments include therapeutic leukoreduction for hyperleukocytosis, hematopoietic stem cell mobilization and collection, and cell sourcing for immunotherapy and research purposes. Geographically, North America accounts for the largest regional share, supported by a concentration of apheresis-capable hospitals, strong healthcare infrastructure, dense biotechnology and pharmaceutical cell therapy development activity, and well-established reimbursement pathways.

• •North America leads the global market, with Europe and East Asia representing significant secondary regions
• •Disposable consumable sets typically generate higher recurring revenue than capital instrument sales
• •End-user segments include hospital apheresis units, independent blood centers, and contract manufacturing organizations supporting cell therapy production

What are the recent trends and outlook?

Market evolution is increasingly shaped by the convergence of apheresis with cell and gene therapy manufacturing, as commercialized autologous immunotherapies require reproducible, GMP-compliant collection processes that leukapheresis platforms provide. Technological trends include next-generation systems with enhanced cell viability profiles, closed-system disposable sets that minimize contamination risk and streamline logistics, and workflow automation that reduces operator variability and improves throughput. The market is expected to sustain its roughly 9 percent annual growth through the early 2030s, underpinned by continued pipeline expansion of cell-based therapies, broader clinical adoption of apheresis-supported treatments, and incremental geographic penetration in healthcare systems across Asia and Latin America.

• •Growing integration of apheresis platforms with closed-system workflows and cell therapy manufacturing pipelines
• •Development of next-generation devices emphasizing cell viability, throughput, and compatibility with downstream cell processing
• •Expansion into new geographic markets and broader clinical indications expected to sustain multi-year market growth